By entering this website, you confirm that you are at least 21 years of age and that you are a qualified researcher or purchasing on behalf of a research institution.
All products sold by BioNex are for laboratory research purposes only. They are not intended for human or animal consumption, and no medical, therapeutic, or diagnostic use is expressed or implied.
You acknowledge that BioNex assumes no liability for misuse, misapplication, or unauthorized use of any product purchased from this website.
By clicking “I Agree,” you accept full responsibility for compliance with all applicable laws and regulations.
Your access is restricted because of your age.
$32.00
CJC-1295 with DAC is a synthetic 29–amino acid analog of growth hormone–releasing hormone (GHRH). It functions as a long-acting GHRH analog designed to stimulate the release of growth hormone (GH) from the pituitary gland. By incorporating a Drug Affinity Complex (DAC), this version was developed to extend half-life while maintaining receptor affinity.
CJC-1295 with DAC is a modified fragment of GHRH with four substituted amino acids that improve stability and pharmacokinetics. The addition of the DAC component further extends its biological activity. DAC achieves this by binding to plasma proteins through a lysine derivative (N-epsilon-3-maleimidopropionamide) at the C-terminus. This modification increases the half-life to approximately 8 days compared to the shorter duration of CJC-1295 without DAC.
Despite its prolonged half-life, CJC-1295 with DAC retains significant affinity for GHRH receptors, similar to the non-DAC version. Researchers continue to explore its potential in stimulating GH release as well as in combination protocols (e.g., with Ipamorelin) for possible synergistic responses.